Drug class
Non-benzodiazepine anxiolytic; benzoxazine derivative and GABAergic modulator
Mechanism of action
Enhances GABA-A receptor-mediated inhibitory neurotransmission by two complementary actions: direct interaction with beta-2/beta-3 receptor subunits and indirect modulation through the mitochondrial translocator protein (TSPO), promoting neurosteroid synthesis that positively modulates GABA-A receptors.
General use cases
- Short-term treatment of anxiety symptoms or adjustment disorders with anxiety in countries where etifoxine is authorised; indication, treatment duration and safety restrictions are product- and jurisdiction-specific
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
